Pembrolizumab: a key for some, but not all, HL

In this issue of Blood, Armand et al describe the long-term outcomes of a phase 2 study of the immune checkpoint inhibitor pembrolizumab in patients with relapsed/refractory classic Hodgkin lymphoma (HL).1

Automated summary

This study examines the long-term outcomes of pembrolizumab, an immune checkpoint inhibitor, in patients with relapsed/refractory classic Hodgkin lymphoma (HL).